198 related articles for article (PubMed ID: 25323095)
21. Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence.
Deniz ML; Kiliç T; Almaata I; Kurtkaya O; Sav A; Pamir MN
Neurosurgery; 2002 Sep; 51(3):753-60; discussion 760. PubMed ID: 12188955
[TBL] [Abstract][Full Text] [Related]
22. Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma.
Gulluoglu S; Sahin M; Tuysuz EC; Yaltirik CK; Kuskucu A; Ozkan F; Sahin F; Ture U; Bayrak OF
Oncol Res; 2017 Aug; 25(7):1177-1188. PubMed ID: 28247842
[TBL] [Abstract][Full Text] [Related]
23. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
24. Chordoma of the skull base: predictors of tumor recurrence.
Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
[TBL] [Abstract][Full Text] [Related]
25. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.
Horbinski C; Oakley GJ; Cieply K; Mantha GS; Nikiforova MN; Dacic S; Seethala RR
Arch Pathol Lab Med; 2010 Aug; 134(8):1170-6. PubMed ID: 20670138
[TBL] [Abstract][Full Text] [Related]
27. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.
Zhang Y; Schiff D; Park D; Abounader R
PLoS One; 2014; 9(3):e91546. PubMed ID: 24621885
[TBL] [Abstract][Full Text] [Related]
29. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
30. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
31. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
32. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
[TBL] [Abstract][Full Text] [Related]
33. Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.
Gao Z; Zhang Q; Kong F; Chen G; Li M; Guo H; Liang J; Bao Y; Ling F
Med Oncol; 2012 Dec; 29(4):2438-44. PubMed ID: 22351250
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor (EGFR) status in chordoma.
Ptaszyński K; Szumera-Ciećkiewicz A; Owczarek J; Mrozkowiak A; Pekul M; Barańska J; Rutkowski P
Pol J Pathol; 2009; 60(2):81-7. PubMed ID: 19886182
[TBL] [Abstract][Full Text] [Related]
35. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
[TBL] [Abstract][Full Text] [Related]
36. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
37. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas.
Yadav R; Sharma MC; Malgulwar PB; Pathak P; Sigamani E; Suri V; Sarkar C; Kumar A; Singh M; Sharma BS; Garg A; Bakhshi S; Faruq M
Neuro Oncol; 2014 Mar; 16(3):372-81. PubMed ID: 24305715
[TBL] [Abstract][Full Text] [Related]
39. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
40. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
Bozzi F; Manenti G; Conca E; Stacchiotti S; Messina A; Dagrada G; Gronchi A; Panizza P; Pierotti MA; Tamborini E; Pilotti S
Neuro Oncol; 2014 Jan; 16(1):72-80. PubMed ID: 24366975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
